IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
IBA to offer QIS® solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics
Louvain-la-Neuve, Belgium, October 1st, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions today announced a new agreement with ARTMS Inc. (a Telix company) for IBA to distribute ARTMS’s proprietary solid-target cyclotron technology, known as QUANTM® Irradiation System (QIS®), to support the expansion of theranostics worldwide.
With QIS® referenced in FDA filings for multiple approved products, ARTMS is the only solid-target cyclotron technology solution in the U.S. with validated gallium-68 (⁶⁸Ga) and zirconium-89 (89Zr) production. For shorter half-life isotopes such as ⁶⁸Ga, QIS® enables decentralized, high-yield, multi-Curie production. Beyond ⁶⁸Ga and 89Zr, ARTMS continues to advance the high-efficiency, large-scale and cost-effective production of other commercially important radiometals, including technetium-99m (99mTc) and copper-64 (64Cu).
Under the partnership agreement, IBA will offer QIS® to new and existing cyclotron customers worldwide, so that the accelerator and solid-target capability can be sourced, installed and serviced through a single supplier. QIS® remains compatible with other cyclotron platforms, and ARTMS continues to serve its existing customers directly. The collaboration aims to accelerate the availability of innovative diagnostic and therapeutic isotopes to support the expansion of theranostics worldwide, through establishing scalable production infrastructures capable of meeting the rapidly growing needs of healthcare providers and patients.